Abstract:Objective To detect the CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation which accepted anticoagulant therapy with Warfarin,analyze the correlations of the CYP2C9 and VKO-RC1 genetic polymorphism with the effective dose and onset time of Warfarin.Methods 222 patients with permanert non-valvular atrial fibrillation were recruited randomly and divided into different groups according to the results of anticoagulant therapy.About the Warfarin drug sensitivity of patient,we defined the low effective dose when accumulated dose of Warfarin less than 12.5 milligrams if international normalized ratio (INR) reached the target value 1.8-3.0,the high effective dose was accumulated dose of Warfarin more than or equal to 12.5 milligrams.According to this,the patients were divided into low effective dose group and high effective dose group.The shot onset time was the onset time of Warfarin less than 10 days if INR reached the target value 1.8-3.0,the long onset time was the onset time more than or equal to 10 days.According to this,the patients were divided into shot onset time group and long onset time group.The correlations of the CYP2C9 and VKORC1 genetic polymorphism with the effective dose and onset time of Warfarin were analyzed.Results (1)The age,serum creatinine(SCr) and the proportion of patients taking beta blockers in low effective dose group were significantly higher than those in high effective dose group (P＜0.05 or 0.01);the body mass index (BMI),white blood cell (WBC) count significandy lower than high effective dose group(P＜0.05);the genetic makeup of CYP2C9 rs1057910 in the two groups was significantly different(P＜0.05).(2)The age,SCr and brain natriuretic peptide (BNP) of patients in shot onset time group were significantly higher than those in long onset time group(P＜0.05 or 0.01);the BMI,WBC and left ventricular ejection fraction (LVEF) significantly lower than long onset time group (P＜0.05 or 0.01);the genetic makeup of VKORC1 rs9923231 and rs10871454 in the two groups were significantly different(P＜0.05 or 0.01).(3) The effective dose of Warfarin in patients with CYP2C9 rs1057910 CA genotype was significantly lower than that with CYP2C9 rs1057910 AA genotype (P＜0.01),the onset time of Warfarin in patients with VKORC1 rs9923231 and rs10871454 CT genotype were significantly lower than those with VKORC1 rs9923231 and rs10871454 TT genotype (P＜0.05 or 0.01).(4)Based on the influence of CYP2C9 and VKORC1 different genotype on Warfarin effective dose and onset time,we defined Warfarin drug sensitivity as highly sensitivity,low sensitivity and routine sensitivity prediction model.Conclusion Combination CYP2C9 and VKORC1 genetic polymorphism with the clinical setting of patients provided a new method for guiding Warfarin anticoagulant therapy rationally in clinic and provided guidance evidence for using genotype to adjust Warfarin dose.

Advances in Research and Clinical Application of Warfarin Pharmacogenomics

Development of Warfarin-Related Pharmacogenomics and Its Prospect of Clinical Application

Role of Warfarin Pharmacogenetic Testing in Clinical Practice

Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway

Individualized treatment of warfarin in atrial fibrillation patients

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation

Study on the Genetic Polymorphism of VKORC1 in Chinese Han Treated by Warfarin Anticoagulant Therapy

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Impact of VKORC1 Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement--a Systematic Review and Meta Analysis.

Interaction Between Chinese Medicine and Warfarin: Clinical and Research Update

Warfarin- A Natural Anticoagulant: A Review of Research Trends for Precision Medication

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Influence of VKORC1-1639G＞A Genetic Polymorphism on Mean Daily Dose of Warfarin in Asian Populations:A Systematic Review and Meta-analysis

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

The correlation of the Warfarin drug sensitivity with CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation

Influence of CYP4F2 Genotype on Warfarin Dose Requirement–a Systematic Review and Meta-Analysis

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

Development of Warfarin Daily Dose Adjustment Formula Based on Geno-type and INR

Effects of CYP2C9 and VKORC1 Genetic Polymorphisms in Chinese Han Population on Maintenance Dosage of Warfarin

System Renew and Meta-Analysis of Effect in Relationship of CYP 2 C9 Genetic Polymorphisms with Warfarin in Chinese Patients